Williams-Sonoma, Inc. (WSM) Stock Price Today
Aura AI Summary
Key Stats
- $25.71BMARKET_CAP
- -VOLUME
- Consumer CyclicalSECTOR
- $240.06FIFTY_TWO_WEEK_HIGH
- $163.62FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $26.55BENTERPRISE_VALUE
- 1.39%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Williams-Sonoma, Inc. (WSM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Williams-Sonoma, Inc. has traded between a low of $163.62 and a high of $240.06, highlighting its annual price range. Buy and sell Williams-Sonoma, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Most Recent News
Juneteenth Exchange in Rancho Cordova unites leaders for innovation, investment, and AI-driven economic growth.
The inaugural Juneteenth Exchange summit in Rancho Cordova gathered over 150 leaders from business, technology, and investment sectors to discuss innovation, economic opportunity, and inclusive leadership. The event highlighted the city's growing app...

Tech sector drops 4.8% in first week of July, worst performer among S&P 500 sectors.
In the first week of July, the Technology sector fell 4.8%, making it the worst-performing sector among the S&P 500. Industrials, Consumer Discretionary, and Materials also declined but to lesser extents. Notably, 22 stocks that more than doubled in ...

Ionis Pharma's Phase-3 trial fails primary endpoint; shares drop 20% amid legal probe.
Ionis Pharmaceuticals announced that its Phase-3 CARDIO-TTRansform trial did not meet its primary endpoint, causing the company's shares to fall over 20%. The trial aimed to reduce cardiovascular death and recurrent events in patients with transthyre...
